temozolomide has been researched along with olaparib in 30 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (3.33) | 29.6817 |
2010's | 17 (56.67) | 24.3611 |
2020's | 12 (40.00) | 2.80 |
Authors | Studies |
---|---|
Adcock, C; Boulter, R; Cockcroft, XL; Copsey, L; Cranston, A; Dillon, KJ; Drzewiecki, J; Garman, S; Gomez, S; Javaid, H; Kerrigan, F; Knights, C; Lau, A; Loh, VM; Martin, NM; Matthews, IT; Menear, KA; Moore, S; O'Connor, MJ; Smith, GC | 1 |
Artali, R; Barbarino, M; Battistuzzi, G; Carollo, V; Dallavalle, S; De Paolis, F; Gallo, G; Giannini, G; Guglielmi, MB; Milazzo, FM; Vesci, L | 1 |
Borghi, D; Busel, AA; Caprera, F; Casale, E; Ciomei, M; Cirla, A; Corti, E; D'Anello, M; Donati, D; Fasolini, M; Felder, ER; Forte, B; Galvani, A; Isacchi, A; Khvat, A; Krasavin, MY; Lupi, R; Montagnoli, A; Orsini, P; Papeo, G; Perego, R; Pesenti, E; Pezzetta, D; Posteri, H; Rainoldi, S; Riccardi-Sirtori, F; Scolaro, A; Sola, F; Zuccotto, F | 1 |
Cao, R; Chen, X; Ji, M; Xu, B; Zhou, J; Zhu, Z | 1 |
Cao, C; Chen, Y; Du, W; Wang, Y; Yang, J; Zhao, L; Zhou, P | 1 |
Feng, Y; Gao, Y; Gong, W; Guo, Y; Huo, CX; Jiang, B; Kuang, X; Liu, X; Liu, Y; Luo, L; Lv, L; Peng, H; Qi, R; Qin, Z; Qiu, M; Ren, B; Su, D; Sun, X; Tang, T; Wang, F; Wang, H; Wang, L; Wang, X; Wang, Z; Wei, M; Wu, Y; Xu, D; Xu, H; Yan, H; Yu, F; Zhao, Y; Zhou, C; Zhu, Y | 1 |
Chen, H; Cheung, F; Chow, JP; Li Lung, M; Man, WY; Mao, M; Nicholls, J; Poon, RY; Tsao, SW | 1 |
Doroshow, JH; Huang, SY; Ji, J; Morris, J; Murai, J; Pommier, Y; Renaud, A; Takeda, S; Teicher, B; Zhang, Y | 1 |
Akbari, MR; Aldape, KD; Denton-Schneider, BR; Hicks, D; Lee, J; McMullin, RP; Moulis, S; Narod, SA; Ramaswamy, S; Sgroi, DC; Singavarapu, R; Steeg, PS; Wittner, BS; Yang, C | 1 |
Doroshow, JH; Ji, J; Morris, J; Murai, J; Pommier, Y; Takeda, S; Zhang, Y | 1 |
Bahrami, A; Benavente, C; Bradley, C; Calabrese, C; Caufield, W; Dyer, MA; Freeman, BB; Gordon, B; Goshorn, R; Griffiths, LM; Hatfield, MJ; Karlström, Å; Loh, A; Miller, GM; Pappo, A; Potter, PM; Sablauer, A; Shelat, AA; Shirinifard, A; Snyder, SE; Stewart, E; Thiagarajan, S; Tsurkan, L; Twarog, NR; Wu, J | 1 |
Engert, F; Fulda, S; Probst, M; Schneider, C; Weiβ, LM | 1 |
Kondo, T; Miyamoto, M; Ohta, T; Watanabe, T; Yamamoto, Y; Yamasaki, H | 1 |
de Stanchina, E; Desmeules, P; Gardner, EE; Lok, BH; Ni, A; Poirier, JT; Powell, SN; Rekhtman, N; Riaz, N; Rudin, CM; Schneeberger, VE; Teicher, BA | 1 |
Bradbury, RH; Brown, H; Caldecott, KW; Cranston, AN; Evers, B; Jaspers, JE; Jones, L; Jonkers, J; Knights, C; Lau, A; Martin, NM; O'Connor, MJ; Odedra, R; Oplustil O'Connor, L; Pajic, M; Rottenberg, S; Rudge, D; Rulten, SL; Ting, A | 1 |
Bautista, W; Ewend, MG; Frady, LN; Gilbert, MR; Kwintkiewicz, J; Liu, Y; Lu, Y; MacDonald, J; Moon, SI; Su, YT; Tech, K; Wu, J; Yang, C | 1 |
Andre, B; Berro, DH; Brachet, PE; Capel, A; Castera, L; Clarisse, B; Coquan, E; Dugué, A; Emery, E; Geffrelot, J; Goardon, N; Grellard, JM; Kao, W; Lacroix, J; Lange, M; Leconte, A; Léger, A; Lelaidier, A; Lequesne, J; Lesueur, P; Stefan, D | 1 |
Masuda, U; Matsumoto, A; Minegaki, T; Miyamoto, K; Moriyama, Y; Nishiguchi, K; Ota, K; Tanahashi, M; Tanaka, M; Tsujimoto, M; Wada, A; Yamamoto, A | 1 |
Brunson, DC; Dershowitz, L; Do, D; Drapkin, BJ; Dubash, TD; Dyson, NJ; Fletcher, JA; Garcia, EG; Haber, DA; Hayes, MN; Hong, X; Iafrate, JA; Iftimia, NA; Karabacak, MN; Langenau, DM; Ligorio, M; Maheswaran, S; Marvin, DL; McCarthy, KM; Moore, JC; Myers, DT; Phat, S; Rawls, JF; Sgroi, DC; Tang, Q; Volorio, A; Welker, AM; Yan, C | 1 |
Byers, LA; Pacheco, JM | 1 |
Cahill, DP; Higuchi, F; Koerner, MVA; Nagashima, H; Ning, J; Wakimoto, H | 1 |
Britt, N; Chudnovsky, Y; Duncan, D; Edgerly, C; Elvin, J; Erlich, RL; Gay, L; Gorelyshev, S; Hemmerich, A; Huang, RSP; Konovalov, A; Kram, DE; McCorkle, J; Miller, V; Ramkissoon, SH; Rankin, A; Ross, JS; Savateev, A; Severson, E; Trunin, Y; Valiakhmetova, A | 1 |
Desar, IME; Fleuren, EDG; Flucke, UE; Hillebrandt-Roeffen, MHS; Mentzel, T; Shipley, J; van Bree, NFHN; van der Graaf, WTA; van Erp, AEM; van Houdt, L; Versleijen-Jonkers, YMH | 1 |
Carruthers, R; Chalmers, AJ; Cruickshank, G; Dunn, L; Erridge, S; Godfrey, L; Halford, S; Hanna, C; Jackson, A; Jefferies, S; Kurian, KM; McBain, C; McCormick, A; Pittman, M; Sleigh, R; Strathdee, K; Watts, C; Williams, K | 1 |
Bindra, RS | 1 |
Alpert, EJ; Brunson, DC; Cobbold, M; Do, D; Drapkin, BJ; Dyson, NJ; Iyer, S; Langenau, DM; Maus, MV; McCarthy, KM; Millar, DG; Moore, JC; Qin, Q; Rawls, JF; Scarfò, I; Stanzione, M; Veloso, A; Wei, Y; Yan, C; Yang, Q; Zhang, S | 1 |
Cacace, A; Dumon, E; Frédérick, R; Grasso, D; Hamelin, L; Lefranc, F; Rossignol, R; Sboarina, M; Sonveaux, E; Sonveaux, P; Thabault, L; Vazeille, T; Zampieri, LX | 1 |
Hirota, K; Ibrahim, MA; Masutani, M; Ooka, M; Sasanuma, H; Shimizu, N; Takeda, S; Tsuda, M; Yamada, K; Yamada, S | 1 |
Drapkin, BJ; Dyson, NJ; Farago, AF; Hadden, MK; LaSalle, TJ; Lawrence, MS; Myers, DT; Phat, S; Sade-Feldman, M; Simoneau, A; Stanzione, M; Wise, JF; Wong, E; Zhong, J; Zou, L | 1 |
Allred, JB; Attia, S; Boikos, SA; Bose, S; Bui, N; Burgess, MA; Chen, JL; Chen, L; Close, JL; Cote, GM; D'Andrea, A; Das, B; Gano, K; George, S; Ingham, M; Ivy, SP; Kochupurakkal, B; Marino-Enriquez, A; Schwartz, GK; Seetharam, M; Shapiro, GI; Thaker, PH | 1 |
3 trial(s) available for temozolomide and olaparib
Article | Year |
---|---|
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Radiotherapy, Intensity-Modulated; Temozolomide | 2019 |
Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Glioblastoma; Humans; Mice; Phthalazines; Piperazines; Rats; Temozolomide | 2020 |
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250).
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Female; Humans; Leiomyosarcoma; Middle Aged; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Phthalazines; Temozolomide; Uterine Neoplasms | 2023 |
27 other study(ies) available for temozolomide and olaparib
Article | Year |
---|---|
4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Dogs; Enzyme Inhibitors; Humans; Mice; Molecular Structure; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Rats; Structure-Activity Relationship | 2008 |
Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Enzyme Inhibitors; Female; Humans; Mice; Mice, SCID; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinazolinones; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2014 |
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cell Proliferation; Dacarbazine; Drug Screening Assays, Antitumor; Female; Heterografts; High-Throughput Screening Assays; Humans; Isoindoles; Mice, Inbred BALB C; Mice, Nude; Microsomes, Liver; Models, Molecular; Neoplasm Transplantation; Pancreatic Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Rats, Sprague-Dawley; Structure-Activity Relationship; Temozolomide; Triple Negative Breast Neoplasms | 2015 |
Discovery of 2-substituted 1H-benzo[d]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in vivo anti-tumor activity.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line; Crystallography, X-Ray; Dacarbazine; Drug Design; Drug Synergism; Enzyme Inhibitors; Heterografts; Inhibitory Concentration 50; Poly (ADP-Ribose) Polymerase-1; Protein Binding; Structure-Activity Relationship; Temozolomide | 2017 |
Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Design; Humans; Ligands; Mice; Neoplasms; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Proteolysis | 2020 |
Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.
Topics: Animals; Binding Sites; Carbazoles; Cell Proliferation; Dogs; Female; Fluorenes; Half-Life; Humans; Indoles; Isoenzymes; Mice; Microsomes; Molecular Docking Simulation; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Rats; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2020 |
PARP1 is overexpressed in nasopharyngeal carcinoma and its inhibition enhances radiotherapy.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Carcinoma; Cell Line; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms, Experimental; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Tissue Array Analysis; Xenograft Model Antitumor Assays | 2013 |
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Topics: Adenosine Triphosphate; Animals; Cell Cycle; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Fluorescence Polarization; Humans; Immunoblotting; Indoles; Inhibitory Concentration 50; Methyl Methanesulfonate; Molecular Structure; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Stereoisomerism; Temozolomide | 2014 |
A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; BRCA1 Protein; Breast Neoplasms; Cell Line; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Mutational Analysis; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Oligonucleotide Array Sequence Analysis; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prognosis; Receptor, ErbB-2; Temozolomide; Transcriptome | 2014 |
Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Survival; Chickens; Dacarbazine; DNA Damage; DNA Repair; Drug Synergism; Enzyme Inhibitors; Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide | 2014 |
Targeting the DNA repair pathway in Ewing sarcoma.
Topics: Animals; Benzimidazoles; Camptothecin; Cell Death; Cell Line, Tumor; Dacarbazine; DNA Breaks, Double-Stranded; DNA Repair; Drug Synergism; Enzyme Inhibitors; Irinotecan; Mice, Nude; Molecular Targeted Therapy; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Sarcoma, Ewing; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Dacarbazine; Dactinomycin; Doxorubicin; Drug Synergism; Etoposide; G2 Phase Cell Cycle Checkpoints; Humans; Ifosfamide; Metabolic Networks and Pathways; Mitochondria; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Sarcoma, Ewing; Temozolomide; Vincristine | 2015 |
Synovial sarcoma cell lines showed reduced DNA repair activity and sensitivity to a PARP inhibitor.
Topics: Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Damage; DNA Repair; Etoposide; Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Radiation, Ionizing; Recombinational DNA Repair; Sarcoma, Synovial; Temozolomide; Topoisomerase II Inhibitors | 2016 |
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Cisplatin; Dacarbazine; Drug Synergism; Etoposide; Gene Expression Regulation, Neoplastic; Genomics; Humans; Indoles; Mice; Nuclear Proteins; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Small Cell Lung Carcinoma; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Repair; Drug Discovery; Genes, BRCA1; Humans; Mice; Neoplasms, Experimental; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Rats; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Repair; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Temozolomide | 2017 |
Synergistic Effects of Olaparib and DNA-damaging Agents in Oesophageal Squamous Cell Carcinoma Cell Lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; DNA Damage; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Esophageal Squamous Cell Carcinoma; Histones; Humans; Irinotecan; Phosphorylation; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide | 2019 |
Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish.
Topics: Animals; Animals, Genetically Modified; Antineoplastic Combined Chemotherapy Protocols; Female; Heterografts; Humans; K562 Cells; Male; Muscle Neoplasms; Neoplasm Transplantation; Phthalazines; Piperazines; Rhabdomyosarcoma; Temozolomide; Xenograft Model Antitumor Assays; Zebrafish | 2019 |
Temozolomide plus PARP Inhibition in Small-Cell Lung Cancer: Could Patient-Derived Xenografts Accelerate Discovery of Biomarker Candidates?
Topics: Animals; Biomarkers; Cell Line, Tumor; Heterografts; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Xenograft Model Antitumor Assays | 2019 |
Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; DNA Mismatch Repair; DNA Repair; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Mice; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Xenograft Model Antitumor Assays | 2020 |
Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response.
Topics: Antineoplastic Agents; Child; Child, Preschool; Female; Glioblastoma; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Temozolomide | 2020 |
Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Child; Desmoplastic Small Round Cell Tumor; Disease Models, Animal; Drug Synergism; Female; Gene Expression; Humans; Male; Mice; Nuclear Proteins; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Xenograft Model Antitumor Assays; Young Adult | 2020 |
Penetrating the brain tumor space with DNA damage response inhibitors.
Topics: Brain Neoplasms; DNA Damage; Glioblastoma; Humans; Phthalazines; Piperazines; Temozolomide | 2020 |
Single-cell imaging of T cell immunotherapy responses in vivo.
Topics: Adolescent; Adult; Animals; Animals, Genetically Modified; Child; Child, Preschool; DNA-Binding Proteins; ErbB Receptors; Female; Humans; Immunotherapy; Immunotherapy, Adoptive; Interleukin Receptor Common gamma Subunit; Male; Mice, Inbred Strains; Phthalazines; Piperazines; Rhabdomyosarcoma; Single-Cell Analysis; T-Lymphocytes; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zebrafish; Zebrafish Proteins | 2021 |
Olaparib Is a Mitochondrial Complex I Inhibitor That Kills Temozolomide-Resistant Human Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Glioblastoma; Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Tumor Cells, Cultured | 2021 |
XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA.
Topics: Adenosine Diphosphate Ribose; Alkylating Agents; DNA; DNA Damage; DNA Repair; Methyl Methanesulfonate; Phthalazines; Piperazines; Poisons; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide | 2022 |
Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer.
Topics: Cell Line, Tumor; DNA; DNA Damage; DNA Replication; Humans; Lung Neoplasms; Phthalazines; Piperazines; Small Cell Lung Carcinoma; Temozolomide | 2022 |